Delivery Order SPE2DB20D3103-SPE2DB25FQ4S2
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Visipaque 320 mg/ml infusion bottles (150 ml units) with a ceiling value of $4,126.40. This firm fixed-price delivery order, which is expected to be completed by August 20, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.9 billion through December 2026. The award was...
- The Defense Logistics Agency awarded a delivery order valued at $1,650.56 to AmerisourceBergen Drug Corp for the supply of Visipaque 320 mg/ml infusion bottles (150 ml) on September 19, 2025, with completion scheduled for September 22, 2025. This firm fixed-price delivery order, issued without a set-aside designation, was competitively awarded and represents a standard pharmaceutical procurement under the agency's medical supply chain operations. AmerisourceBergen Drug Corp, headquartered in...
- The Defense Logistics Agency awarded a $1,650.56 delivery order to AmerisourceBergen Drug Corp for Visipaque 320 mg/ml infusion bottles (150 ml) on September 25, 2025, with completion scheduled for September 26, 2025. This is a firm fixed price delivery order with no set-aside designation, issued under open competition. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child contract under the vendor's larger...
- The Defense Logistics Agency awarded a $3,004.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Visipaque 320 mg/mL, a contrast agent used in medical imaging procedures. This award, made on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a child order under a larger contract vehicle. The delivery location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This is a non-set-aside competitive award, reflecting...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,038.55 to AmerisourceBergen Drug Corp for the supply of Visipaque 320 mg/mL infusion bottles (150 mL units). This firm fixed-price delivery order, awarded on August 15, 2025, represents a non-competitive set-aside procurement and will be fulfilled by AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, with an ultimate completion date of August 18, 2025. Visipaque is a contrast medium used in...
- The Defense Logistics Agency awarded a delivery order valued at $1,650.56 to AmerisourceBergen Drug Corp for Visipaque 320 mg/mL intravenous solution in 150 mL bottles. This competitive award, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, reflects a firm fixed-price contract type with no set-aside designation. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $2,063.20 to AmerisourceBergen Drug Corp for the supply of Visipaque 320 mg/ml infusion bottles (150 ml) on August 28, 2025, with completion targeted for August 29, 2025. This firm fixed-price delivery order represents a non-competitive set-aside procurement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued under the company's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Visipaque 320 mg/ml in 100-milliliter bottles, valued at $1,335.12. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by August 21, 2025, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Visipaque 270 mg/ml in 150 ml bottles, valued at $1,599.09 with a firm fixed price arrangement. The contract requires completion by September 8, 2025, and represents a non-set-aside award issued through open competition. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99...
- The Defense Logistics Agency awarded a delivery order valued at $4,283.00 to AmerisourceBergen Drug Corp for the supply of Visipaque 270 mg/ml in 100ml bottles. The contract, awarded on May 22, 2025, with an ultimate completion date of May 23, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the performing location for this order. This delivery order is issued under AmerisourceBergen...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ4S2Delivery Order
The Defense Logistics Agency awarded a $4,246.40 delivery order to AmerisourceBergen Drug Corp for Visipaque 320 mg/mL infusion bottles (150 mL) on September 24, 2025, with completion expected by September 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a single line-item procurement of this contrast medium pharmaceutical product to support federal medical supply needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs and other government healthcare systems worldwide. The company's portfolio of federal contracts demonstrates extensive capability in delivering both brand-name and generic pharmaceuticals across multiple therapeutic domains through the DLA's Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 9/24/25 |